Patients treated with pembrolizumab plus paclitaxel with or without bevacizumab had a statistically significant and clinically meaningful improvement in PFS, regardless of PD-L1 status. Topline ...

Most millionaires don't consider themselves wealthy. So what does it really mean to be rich? Best money market account rates today, December 18, 2025 (earn up to 4.25% APY) ...

Please provide your email address to receive an email when new articles are posted on . Women with advanced ovarian cancer derived significant quality-adjusted PFS benefit from niraparib compared with ...

26,652 people played the daily Crossword recently. Can you solve it faster than others?26,652 people played the daily Crossword recently. Can you solve it faster than others?

Please provide your email address to receive an email when new articles are posted on . The addition of pyrotinib to trastuzumab and docetaxel improved 4-year OS vs. placebo for patients with ...

Enhertu lengthened the time to progression in patients with HR-positive, HER2-low or -ultralow metastatic breast cancer. Enhertu (fam-trastuzumab deruxtecan-nxki; Enhertu) improved progression-free ...

The use of liquid biopsy comprehensive genomic profiling to identify the molecular landscape of patients with metastatic colorectal cancer who are candidates for anti-EGFR rechallange therapy: ...

Elacestrant significantly improves PFS in ER-positive, HER2-negative metastatic breast cancer with ESR1 mutations compared to standard-of-care treatments. The EMERALD trial showed elacestrant's ...

Metformin use in mCRC patients improved PFS during first-line 5-fluorouracil-based chemotherapy, but no OS benefit was observed. The study suggests metformin's potential as an adjunct therapy in mCRC, ...